Background:
-
PDZ and LIM domain protein 2 (PDLIM2) acts as tumor suppressor by downregulating NF-kB and STAT3 signaling, modulating inflammation, immune response, and cell survival.
-
Mouse models have demonstrated that downregulation of PDLIM2 leads to PD-1 immune blockade and chemotherapy resistance.
-
We characterized the genomic and immunological landscape of PDLIM2 expression in Adenocarcinoma non-small cell lung cancer (NSCLC).